Compounds for the treatment of neuromuscular disorders

A compound of Formula (I):

• wherein:
• R1 is selected from the group consisting of C1-2 alkyl, C2 alkenyl, C2 alkynyl, CN, CF3, NO2, F, Cl, Br, and I;
• R2 is selected from the group consisting of C1-5 alkyl optionally be substituted with one or more, identical or different, substituents R6, C2-5 alkenyl optionally be substituted with one or more, identical or different, substituents R6, C2-5 alkynyl optionally be substituted with one or more, identical or different, substituents R6, C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R6, phenyl optionally substituted with one or more, identical or different, substituents R9, and 5-6 membered aromatic heterocycle optionally substituted with one or more, identical or different, substituents R7;
• R3 is selected from the group consisting of deuterium, Cl and F;
• R4 is selected from the group consisting of H, deuterium, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and C3-5 cycloalkyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
• R5 is selected from the group consisting of H, C1-5 alkyl optionally substituted with one or more, identical or different, substituents R8, C2-5 alkenyl optionally substituted with one or more, identical or different, substituents R8, C2-5 alkynyl optionally substituted with one or more, identical or different, substituents R8, C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R8, phenyl optionally substituted with one or more, identical or different, substituents R9, and benzyl optionally substituted with one or more, identical or different, substituents R9;
• R6 is independently selected from the group consisting of deuterium, F, —CN, —O—C1-5 alkyl, —O—C3-5 cycloalkyl, —S—C1-5 alkyl, and —S—C3-5 cycloalkyl, wherein the —O—C1-5 alkyl, —O—C3-5 cycloalkyl, —S—C1-5 alkyl, and —S—C3-5 cycloalkyl may optionally be substituted with one or more, identical or different, substituents R8;
• R7 is independently selected from the group consisting deuterium, F, C1, —CN, C3-5 cycloalkyl, —O—C1-5 alkyl, —O—C3-5 cycloalkyl, —S—C1-5 alkyl, and —S—C3-5 cycloalkyl, wherein the C3-5 cycloalkyl, —O—C1-5 alkyl, —O—C3-5 cycloalkyl, —S—C1-5 alkyl, and —S—C3-5 cycloalkyl may optionally be substituted with one or more, identical or different, substituents R8;
• R8 is independently selected from the group consisting of deuterium and F;
• R9 is independently selected from the group consisting of deuterium, methoxy, nitro, cyano, Cl, Br, I, and F;
• X is a bond or selected from the group consisting of —O—, —S—, —CH2—, —CHR6—, and —C(R6)2—;
• and
• n is an integer 0, 1, 2, or 3;
• or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.